» Articles » PMID: 36231450

Efficacy of Mouth Rinses and Nasal Spray in the Inactivation of SARS-CoV-2: A Systematic Review and Meta-Analysis of and Studies

Overview
Publisher MDPI
Date 2022 Oct 14
PMID 36231450
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a global and evolving pandemic associated with heavy health and financial burdens. Considering the oral cavity as the major reservoir for SARS-CoV-2, a systematic review and meta-analysis were conducted to assess the efficacy of mouth rinses and nasal sprays in reducing the salivary viral load of SARS-CoV-2. All and studies that assessed the virucidal efficacy of mouth rinses and nasal sprays against SARS-CoV-2 and were published in the English language from December 2019 to April 2022 were considered for analyses. Special Medical Subject Headings terms were used to search Pubmed, Scopus, Embase Ovid, and Web of Science databases. The toxicological data reliability assessment tool (ToxRToool) was used to assess the quality of the included studies. Thirty-three studies (11 and 22 ) were deemed eligible for inclusion in this analysis. Results of the pooled data showed that povidone-iodine is the most efficacious intervention in terms of reducing the SARS-CoV-2 salivary viral load, followed by chlorhexidine. The mean difference in the viral load was 86% and 72%, respectively. Similarly, povidone-iodine was associated with the highest log reduction value (LRV) , followed by cetylpyridinium chloride, (LRV = 2.938 ( < 0.0005) and LRV = 2.907 ( = 0.009), respectively). Povidone-iodine-based oral and nasal preparations showed favourable results in terms of reducing SARS-CoV-2 viral loads both and . Considering the limited number of patients , further studies among larger cohorts are recommended.

Citing Articles

Efficacy of povidone-iodine nasal rinse and mouth wash in COVID-19 management: a prospective, randomized pilot clinical trial (povidone-iodine in COVID-19 management).

Alsaleh S, Alhussien A, Alyamani A, Alhussain F, Alhijji A, Binkhamis K BMC Infect Dis. 2024; 24(1):271.

PMID: 38429662 PMC: 10905910. DOI: 10.1186/s12879-024-09137-y.


Efficacy of mouthwash on reducing salivary SARS-CoV-2 viral load and clinical symptoms: a systematic review and meta-analysis.

Zhang M, Meng N, Duo H, Yang Y, Dong Q, Gu J BMC Infect Dis. 2023; 23(1):678.

PMID: 37821800 PMC: 10568889. DOI: 10.1186/s12879-023-08669-z.


Why not to pick your nose: Association between nose picking and SARS-CoV-2 incidence, a cohort study in hospital health care workers.

Lavell A, Tijdink J, Buis D, Smulders Y, Bomers M, Sikkens J PLoS One. 2023; 18(8):e0288352.

PMID: 37531335 PMC: 10395815. DOI: 10.1371/journal.pone.0288352.


Administration of Clinical COVID-19 Mouthwashing Protocol and Potential Modulation of Pediatric Oral Bacterial Prevalence of : A Pilot Study.

Sodhi P, Jiang Y, Lin S, Downey J, Sorenson C, Shayegh M Pediatr Rep. 2023; 15(3):414-425.

PMID: 37489412 PMC: 10366775. DOI: 10.3390/pediatric15030038.


Aerosol in the oral health-care setting: a misty topic.

Van der Weijden F Clin Oral Investig. 2023; 27(Suppl 1):23-32.

PMID: 37162570 PMC: 10170433. DOI: 10.1007/s00784-023-05034-x.


References
1.
Figueroa J, Lombardo M, Dogliotti A, Flynn L, Giugliano R, Simonelli G . Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. Int J Gen Med. 2021; 14:6277-6286. PMC: 8493111. DOI: 10.2147/IJGM.S328486. View

2.
Yuki K, Fujiogi M, Koutsogiannaki S . COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215:108427. PMC: 7169933. DOI: 10.1016/j.clim.2020.108427. View

3.
van Doremalen N, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B . Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020; 382(16):1564-1567. PMC: 7121658. DOI: 10.1056/NEJMc2004973. View

4.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

5.
Costa D, Brites C, Vaz S, de Santana D, Nunes Dos Santos J, Ramos Cury P . Chlorhexidine mouthwash reduces the salivary viral load of SARS-CoV-2: A randomized clinical trial. Oral Dis. 2021; 28 Suppl 2:2500-2508. DOI: 10.1111/odi.14086. View